(AOF) – Mauna Kea Technologies publishes a turnover of 10.5 million euros in 2023, an increase of 42% compared to 2022. The inventor of Cellvizio, a multidisciplinary platform for confocal laser endomicroscopy using miniprobe and by needle highlights the record growth in sales of PPU (pay-as-you-go program) which represented 63% of sales in the fourth quarter: this growth is 109% in the 4th quarter of 2023, and 57% over the year.
“This model provides greater stability with recurring and regular revenue, provides access to a significant volume of patients and generates significant operational leverage as system usage increases,” the company emphasizes.
“For the year 2023, growth was mainly driven by the United States and the contribution of the joint venture with Tasly,” underlines Mauna Kea.
“With a promising pipeline of new partnerships and continued support from the international medical community, I am optimistic about the future achievements this new year has in store for us,” says CEO Sacha Loiseau.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.